Tung A, Maliniak K, Tenicela R, et al. Intrathecal morphine for intraoperative and postoperative analgesia[J].JAMA,1980, 244(23):2637-2638.
[2]
Timothy R, Jason E, Salim Hayek, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines[J]. Neuromodulation,2017,20(4):405-406.
Sommer B, Karageorgos N, AlSharif M, et al. Long-term outcome and adverse events of intrathecal opioid therapy for nonmalignant pain syndrome[J]. Pain Pract, 2020, 20(1):8-15.
Timothy R D, Jason E P, Michael C H, et al. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options[J]. Pain Med, 2019, 20(4):784-798.
[10]
Ying H, Xihan L, Tong Z, et al. Efficacy and safety of ropivacaine addition to intrathecal morphine for pain management in intractable cancer[J]. Mediat Inflamm, 2015,2015:439014.
[11]
A Blanie, S Figueiredo, G Lorre, et al. Transient neurologic symptoms (tns) after intrathecal injection of ropivacaine through a dural tap during an attempted epidural for labour pain relief. anaesth crit[J]. Care Pain Med, 2017, 36(5):325-326.
Li H, Yang L, Guo Z, et al. Successful treatment of refractory cancer pain with morphine and ropivacaine: a case report[J]. Medicine (Baltimore), 2017,96(22):e7052.
[14]
Flack S H, Anderson C M, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs[J]. Anesth Analg, 2011,112(2):460-464.
2021, Vol. 32 
